The Food and Drugs Authority (FDA) has named Professor Kwabena Frimpong-Manso Opuni as its Acting Chief Executive Officer, effective Monday, 14 July 2025.
He steps into the role following the departure of Dr. Delese Mimi Darko, who has been appointed Director General of the Africa Medicines Agency (AMA). Dr. Darko, who led the FDA since 2017, is widely credited with strengthening regulatory systems and advancing consumer protection during her time in office.
Professor Opuni, a seasoned expert in public health and regulatory affairs, previously served as Chairman of the FDA Board. He brings years of experience in institutional governance and policy development, positioning him well to lead the Authority through its next phase.
In a statement confirming the appointment, the FDA praised Prof. Opuni’s leadership qualities and expressed confidence in his ability to uphold the Authority’s core mission of protecting public health.
“The Authority congratulates Professor Opuni and looks forward to his stewardship in advancing the FDA’s regulatory mandate,” the statement said.
Prof. Opuni’s appointment comes at a time when regulatory institutions like the FDA are playing an increasingly critical role in public health and consumer safety, amid rising concerns over product quality and cross-border health threats.
